{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T09:14:25Z","timestamp":1719566065296},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T00:00:00Z","timestamp":1253059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s10620-009-0969-z","type":"journal-article","created":{"date-parts":[[2009,9,14]],"date-time":"2009-09-14T19:16:33Z","timestamp":1252955793000},"page":"2058-2062","source":"Crossref","is-referenced-by-count":6,"title":["Reduction in Neutrophil Count During Hepatitis\u00a0C Treatment: Drug Toxicity or Predictor of Good Response?"],"prefix":"10.1007","volume":"55","author":[{"given":"Gerardo","family":"Alvarez-Uria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy N.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisa J.","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Javier","family":"Vilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,16]]},"reference":[{"key":"969_CR1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","volume":"39","author":"DB Strader","year":"2004","unstructured":"Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis\u00a0C. Hepatology. 2004;39:1147\u20131171.","journal-title":"Hepatology"},{"key":"969_CR2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev.micro.55.1.255","volume":"55","author":"GC Sen","year":"2001","unstructured":"Sen GC. Viruses and interferons. Annu Rev Microbiol. 2001;55:255\u2013281.","journal-title":"Annu Rev Microbiol"},{"key":"969_CR3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","volume":"436","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis\u00a0C. Nature. 2005;436:967\u2013972.","journal-title":"Nature"},{"key":"969_CR4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/gut.2004.057893","volume":"54","author":"M Schmid","year":"2005","unstructured":"Schmid M, Kreil A, Jessner W, et\u00a0al. Suppression of haematopoiesis during therapy of chronic hepatitis\u00a0C with different interferon alpha mono and combination therapy regimens. Gut. 2005;54:1014\u20131020.","journal-title":"Gut"},{"key":"969_CR5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, et\u00a0al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis\u00a0C virus infection. N Engl J Med. 2002;347:975\u2013982.","journal-title":"N Engl J Med"},{"key":"969_CR6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et\u00a0al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis\u00a0C: a randomised trial. Lancet. 2001;358:958\u2013965.","journal-title":"Lancet"},{"key":"969_CR7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, et\u00a0al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis\u00a0C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346\u2013355.","journal-title":"Ann Intern Med"},{"key":"969_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228\u2013237.","journal-title":"Cancer"},{"key":"969_CR9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","volume":"130","author":"JL Dienstag","year":"2006","unstructured":"Dienstag JL, McHutchison JG. American gastroenterological association technical review on the management of hepatitis\u00a0C. Gastroenterology. 2006;130:231\u2013264. quiz 214\u2013237.","journal-title":"Gastroenterology"},{"key":"969_CR10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","volume":"36","author":"A Soza","year":"2002","unstructured":"Soza A, Everhart JE, Ghany MG, et\u00a0al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis\u00a0C. Hepatology. 2002;36:1273\u20131279.","journal-title":"Hepatology"},{"key":"969_CR11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.21932","volume":"46","author":"IM Jacobson","year":"2007","unstructured":"Jacobson IM, Brown RS Jr, Freilich B, et\u00a0al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis\u00a0C patients: a randomized trial. Hepatology. 2007;46:971\u2013981.","journal-title":"Hepatology"},{"key":"969_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","volume":"132","author":"ML Shiffman","year":"2007","unstructured":"Shiffman ML, Ghany MG, Morgan TR, et\u00a0al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis\u00a0C. Gastroenterology. 2007;132:103\u2013112.","journal-title":"Gastroenterology"},{"key":"969_CR13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2893.2007.00870.x","volume":"14","author":"J Koirala","year":"2007","unstructured":"Koirala J, Gandotra SD, Rao S, et\u00a0al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat. 2007;14:782\u2013787.","journal-title":"J Viral Hepat"},{"key":"969_CR14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2893.2007.00956.x","volume":"15","author":"ZM Younossi","year":"2008","unstructured":"Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, Sjogren M, Farmer D, Ramsey L, Terra K, Gujral H, Gurung C, Srishord M, Fang Y. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis\u00a0C treatment. J Viral Hepat. 2008;15:370\u2013378.","journal-title":"J Viral Hepat"},{"key":"969_CR15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2007.11.020","volume":"6","author":"KL Lindsay","year":"2008","unstructured":"Lindsay KL, Morishima C, Wright EC, et\u00a0al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis\u00a0C. Clin Gastroenterol Hepatol. 2008;6:234\u2013241.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"969_CR16","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1128\/JVI.02640-06","volume":"81","author":"MW Taylor","year":"2007","unstructured":"Taylor MW, Tsukahara T, Brodsky L, et\u00a0al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis\u00a0C virus distinguish responders from nonresponders to antiviral therapy. J Virol. 2007;81:3391\u20133401.","journal-title":"J Virol"},{"key":"969_CR17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","volume":"128","author":"L Chen","year":"2005","unstructured":"Chen L, Borozan I, Feld J, et\u00a0al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis\u00a0C viral infection. Gastroenterology. 2005;128:1437\u20131444.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0969-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-009-0969-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0969-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:42:52Z","timestamp":1559230972000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-009-0969-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,16]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s10620-009-0969-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,16]]}}}